Relay Therapeutics, Inc.

RLAY • Biotechnology

$19.04

▲ +0.03 (+0.16%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$3.86B

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Positive revenue growth · 29.5%Manageable debt level · 0.06Healthy liquidity · 22.61Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$19.04

Change0.16%

Shares Out202.85M

Market Cap$3.86B

Enterprise Value$3.77B

52W Range3.02 - 19.93

Beta1.75

P/E-13.50

P/S373.16

P/B4.34

P/FCF-14.67

EV/Sales364.42

Price$19.04

Change0.16%

Shares Out202.85M

Market Cap$3.86B

Enterprise Value$3.77B

52W Range3.02 - 19.93

Beta1.75

P/E-13.50

P/S373.16

P/B4.34

P/FCF-14.67

EV/Sales364.42

EV/EBITDA-12.64

EV/FCF-14.32

Earnings Yield-7.41%

FCF Yield-6.82%

Dividend Yield0.00%

Gross Margin76.83%

Oper. Margin-19.72%

Profit Margin-18.01%

Debt/Eq0.06

Current Ratio22.61

Quick Ratio22.61

Target$26.25

Target Upside37.87%

Target Median$27.50

Target Range18.00 - 31.00

Volume5.71M

Avg Volume4.29M

EPS Surprise-0.05

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

51/100

Why this score▼

Positive revenue growth · 29.5%Manageable debt level · 0.06Healthy liquidity · 22.61Weak profitability

Analyst view

Analyst sentiment and price target

RLAY

Analyst sentiment

Based on 15 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$18.00

Mean

$26.13

Median

$27.00

High

$31.00

Company Overview

IPO: 7/16/2020

Industry: Biotechnology

P/B i: 4.34

Debt / Equity i: 0.06

Operating Margin: -1971.59%

Net Margin: -1800.58%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.06

Current Ratio: 22.61

Quick Ratio: 22.61

Status: Good

Insider Transactions

Recent executive and insider activity

Bergstrom Donald A

Transaction: 07/28/2026

SELL

Change

-2,237

Price

$18.61

Filing

07/30/2026

Type

SELL

Rahmer Peter

Transaction: 07/28/2026

SELL

Change

-748

Price

$18.61

Filing

07/30/2026

Type

SELL

Catinazzo Thomas

Transaction: 07/28/2026

SELL

Change

-1,459

Price

$18.61

Filing

07/30/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Bergstrom Donald A	SELL	-2,237	$18.61	07/28/2026	07/30/2026
Rahmer Peter	SELL	-748	$18.61	07/28/2026	07/30/2026
Catinazzo Thomas	SELL	-1,459	$18.61	07/28/2026	07/30/2026
Patel Sanjiv	SELL	-48,199	$19.58	07/07/2026	07/08/2026
Catinazzo Thomas	SELL	-17,717	$18.69	07/06/2026	07/08/2026
Bergstrom Donald A	SELL	-8,660	$18.71	07/06/2026	07/08/2026
Patel Sanjiv	BUY	+3,056	$6.95	06/30/2026	07/08/2026
Rahmer Peter	SELL	-50,000	$19.09	06/30/2026	07/02/2026
Bergstrom Donald A	SELL	-93,456	$4.12	06/22/2026	06/24/2026
Bergstrom Donald A	SELL	-93,456	$16.94	06/22/2026	06/24/2026
Catinazzo Thomas	SELL	-61,563	$5.22	06/22/2026	06/24/2026
Catinazzo Thomas	SELL	-51,560	$16.97	06/22/2026	06/24/2026
COATS LONNEL	BUY	+32,947	$14.09	06/09/2026	06/10/2026
Murcko Mark	BUY	+32,947	$14.09	06/09/2026	06/10/2026
INGRAM DOUGLAS S	BUY	+32,947	$14.09	06/09/2026	06/10/2026
Borisy Alexis	BUY	+32,947	$14.09	06/09/2026	06/10/2026
HILL LINDA A	BUY	+32,947	$14.09	06/09/2026	06/10/2026
Dable Habib J	BUY	+32,947	$14.09	06/09/2026	06/10/2026
Mazumdar Claire	BUY	+32,947	$14.09	06/09/2026	06/10/2026
Catinazzo Thomas	SELL	-17,717	$12.86	05/14/2026	05/14/2026

About the Company

Relay Therapeutics, Inc.

Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.

Source - link

Peers

AMLX CVAC IMTX INBX NKTR ORIC SANA SNDX UPB ZBIO

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Relay Therapeutics CFO Sells 17,717 Shares for $350,000

The sale had an approximate value of nearly $350,000. The transaction reduced the executive's direct equity position by 11%.

The Motley Fool

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:

GlobeNewsWire

Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE

Bank of America Corp DE raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ: RLAY) by 86.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,937,695 shares of the company's stock after purchasing an additional 896,746 shares during the

Defense World

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

Zacks Investment Research

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.

Zacks Investment Research

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-05	-0.36321	-0.41	-0.04679
2026-02-26	-0.38	-0.32	0.06
2025-11-06	-0.39	-0.43	-0.04
2025-08-07	-0.49	-0.41	0.08
2025-05-05	-0.5	-0.46	0.04
2025-02-26	-0.57	-0.45	0.12
2024-11-06	-0.77	-0.63	0.14
2024-08-06	-0.73	-0.69	0.04
2024-05-02	-0.7	-0.62	0.08
2024-02-22	-0.76	-0.67	0.09
2023-11-02	-0.83	-0.54	0.29
2023-08-08	-0.78	-0.81	-0.03